Recent Progress and Challenges in the Development of Antisense Therapies for Myotonic Dystrophy Type 1

por De Serres-Bérard, Thiéry, Ait Benichou, Siham, Jauvin, Dominic, Boutjdir, Mohamed, Puymirat, Jack, Chahine, Mohamed
Publicado 2022

Antisense oligonucleotides as a potential treatment for brain deficits observed in myotonic dystrophy type 1

por Ait Benichou, Siham, Jauvin, Dominic, De Serres-Bérard, Thiéry, Pierre, Marion, Ling, Karen K., Bennett, C. Frank, Rigo, Frank, Gourdon, Genevieve, Chahine, Mohamed, Puymirat, Jack
Publicado 2022

Targeting DMPK with Antisense Oligonucleotide Improves Muscle Strength in Myotonic Dystrophy Type 1 Mice

por Jauvin, Dominic, Chrétien, Jessina, Pandey, Sanjay K., Martineau, Laurie, Revillod, Lucille, Bassez, Guillaume, Lachon, Aline, McLeod, A. Robert, Gourdon, Geneviève, Wheeler, Thurman M., Thornton, Charles A., Bennett, C. Frank, Puymirat, Jack
Publicado 2017

Peptide-conjugated oligonucleotides evoke long-lasting myotonic dystrophy correction in patient-derived cells and mice

por Klein, Arnaud F., Varela, Miguel A., Arandel, Ludovic, Holland, Ashling, Naouar, Naira, Arzumanov, Andrey, Seoane, David, Revillod, Lucile, Bassez, Guillaume, Ferry, Arnaud, Jauvin, Dominic, Gourdon, Genevieve, Puymirat, Jack, Gait, Michael J., Furling, Denis, Wood, Matthew J.A.
Publicado 2019